+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
ID07684599

Study of Mocertatug Rezetecan Combined With Immunotherapy Compared to Immunotherapy Alone for Maintenance Treatment of Mismatch Repair Proficient Endometrial Cancer

Led by GlaxoSmithKline · Updated on 2026-11-03

610

Participants Needed

12

Research Sites

112 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how well mocertatug rezetecan Mo-Rez combined with a physicians choice of immunotherapy dostarlimab or pembrolizumab works as maintenance treatment for participants with advanced or recurrent mismatch repair proficient endometrial cancer. This study compares this combination to immunotherapy alone, which is the current standard of care, and also assesses the safety, tolerability, and impact on participants quality of life. The trial is a Phase 3 randomized, open-label study sponsored by GlaxoSmithKline. Participants are assigned to one of two groups one group receives mocertatug rezetecan plus either dostarlimab or pembrolizumab, while the other group receives only the physicians choice of immunotherapy. The study treatment starts within 3 to 9 weeks after completion of first-line therapy, which includes chemotherapy and immunotherapy, and continues as maintenance therapy. The treatment duration and follow-up periods extend up to several years to monitor outcomes. During the study, participants will undergo regular assessments including scans and laboratory tests to monitor disease progression and side effects. Researchers will measure progression-free survival by blinded independent central review, overall survival, response rates, duration of response, and quality of life using specific questionnaires. Safety evaluations will include monitoring adverse events, vital signs, and laboratory parameters. The total participation time may last up to approximately 260 weeks to gather comprehensive data on treatment effects and tolerability.

CONDITIONS

Brief Title

A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

Research Team

U

US GSK Clinical Trials Call Center

E

EU GSK Clinical Trials Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here